US biotechnology company Illumina has pledged $ 100 m over a ten - year period to a new , venture capital ( VC ) firm known as Illumina Ventures . This new organisation will share the same values and vision for the future as its parent company , although it will operate independently . Nevertheless , a condition of this investment is Illumina becoming the majority limited partner in the new firm 's first fund . This new VC fund will invest in incubator - based companies that are working on projects dedicated to exploring the future of the human genome . Examples of innovative projects include cutting - edge nucleic acid sequencing techniques , products that improve the genomics ecosystem and how this can be utilised to improve health and wellbeing . This fund is the latest in a series where the goal is the expansion of genomics technologies and companies via investment in startups .
US biotechnology company Illumina has pledged $100m over a ten-year period to a new, venture capital (VC) firm known as Illumina Ventures. This new organisation will share the same values and vision for the future as its parent company, although it will operate independently. Nevertheless, a condition of this investment is Illumina becoming the majority limited partner in the new firm's first fund. This new VC fund will invest in incubator-style companies that are working on projects dedicated to unlocking the potential of the human genome. Examples of innovative projects include cutting-edge nucleic acid sequencing techniques, products that improve the genomics ecosystem and how this can be utilised to improve health and wellbeing. This initiative is the latest in a series where the goal is the expansion of genomics technologies and companies via investment in startups.